IgM-RF also correlates with a negative prognosis in terms of both overall survival (OS) and progression-free survival (PFS) in metastatic NSCLC patients in treatment with an anti-PD-1 ICI, with the worst outcome shown by patients with titers greater than 50 IU/mL [51,61]. Here, CD40LG is linked to non-small cell lung carcinoma.